Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

8.360 -0.040 (-0.48%)
Streaming Delayed Price Updated: 9:38 AM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
These two biotechs only have one marketable therapy each, but both have blockbuster potential. 
Via The Motley Fool
News headline image
ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗
ARS Pharma SPRY Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗
ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion. 
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For ARS Pharmaceuticals ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Outlook For ARS Pharmaceuticals ↗
 
Via Benzinga
News headline image
ARS Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗
ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns. 
Via Benzinga
News headline image
ARS Pharma Sales Jump 3,040% in Q2 ↗
Via The Motley Fool
News headline image
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists ↗
ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway. 
Via Chartmill
News headline image
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs ↗
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said. 
Via Benzinga
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Where ARS Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings For ARS Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. ↗
The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions. 
Via Investor's Business Daily
News headline image
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment ↗
FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors. 
Via Benzinga
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
News headline image
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray ↗
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
Via Investor's Business Daily
News headline image
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 ↗
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
Via Benzinga
News headline image
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned ↗
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
Via Benzinga
News headline image
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.